The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery.


Journal

ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013

Informations de publication

Date de publication:
07 06 2021
Historique:
received: 18 01 2021
pubmed: 8 4 2021
medline: 27 1 2022
entrez: 7 4 2021
Statut: ppublish

Résumé

Phenotypic drug discovery has a long track record of delivering innovative drugs and has received renewed attention in the last few years. The promise of this approach, however, comes with several challenges that should be addressed to avoid wasting time and resources on drugs with undesired modes of action or, worse, false-positive hits. In this set of best practices, we go over the essential steps of phenotypic drug discovery and provide guidance on how to increase the chance of success in identifying validated and relevant chemical starting points for optimization: selecting the right assay, selecting the right compound screening library and developing appropriate hit validation assays. Then, we highlight the importance of initiating studies to determine the mode of action of the identified hits early and present the current state of the art.

Identifiants

pubmed: 33825353
doi: 10.1002/cmdc.202100041
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1736-1739

Subventions

Organisme : EFMC

Informations de copyright

© 2021 Wiley-VCH GmbH.

Références

J. Eder, R. Sedrani, C. Wiesmann, Nat. Rev. Drug Discovery 2014, 13, 577-587.
D. C. Swinney, J. Anthony, Nat. Rev. Drug Discovery 2011, 10, 507-519.
J. G. Moffat, F. Vincent, J. A. Lee, J. Eder, M. Prunotto Nat. Rev. Drug Discovery 2017, 16, 531-543.
P. P. Chamberlain, L. A. D'Agostino, J. M. Ellis, J. D. Hansen, M. E. Matyskiela, J. J. McDonald, J. R. Riggs, L. G. Hamann, ACS Med. Chem. Lett. 2019, 10, 1592-1602.
N. A. Naryshkin, M. Weetall, A. Dakka, J. Narasimhan, X. Zhao, Z. Feng, K. K. Y. Ling, G. M. Karp, H. Qi, M. G. Woll, et al., Science 2014, 345, 688-693.
J. Quancard, B. Cox, D. Finsinger, S. M. Guéret, I. V. Hartung, H. F. Koolman, J. Messinger, G. Sbardella, S. Laufer, ChemMedChem 2020, 15, 2388-2390.
D. Haasen, U. Schopfer, C. Antczak, C. Guy, F. Fuchs, P. Selzer, Assay Drug Dev. Technol. 2017, 15, 239-246.
F. Vincent, P. Loria, M. Pregel, R. Stanton, L. Kitching, K. Nocka, R. Doyonnas, C. Steppan, A. Gilbert, T. Schroeter, M. Peakman, Sci. Transl. Med. 2015, 7, 293ps15.
A. M. Wassermann, L. M. Camargo, D. S. Auld, Front. Pharmacol. 2014, 5, a164, 1-12.
F. Vincent, P. M. Loria, A. D. Weston, C. M. Steppan, R. Doyonnas, Y. Wang, K. L. Rockwell, M. Peakman, Cell Chem. Biol. 2020, 27, 1332-1346.
W. G. Kaelin, Nat. Rev. Cancer. 2017, 17, 441-450.
F. M. Drawnel, J. D. Zhang, E. Kueng, N. Aoyama, F. Benmansour, A. A. Del Rosario, S. Jensen Zoffmann, F. Delobel, M. Prummer, F. Weibel, C. Carlson, B. Anson, R. Iacone, U. Certa, T. Singer, M. Ebeling, M. Prunotto, Cell Chem. Biol. 2017, 24, 624-634.
F. I. Saldivar-Gonzalez, J. J. Naveja, O. Palomino-Hernandez, J. L. Medina-Franco, RSC Adv. 2017, 7, 632.
K. Kubota, M. Funabashi, Y. Ogura, Biochem. Biophys, Acta. 2019, 1867, 22-27.
J. Lee, M. Bogyo, Curr. Opin. Chem. Biol. 2013, 17, 118-126.
R. Friedman Ohana, T. A. Kirkland, C. C. Woodroofe, S. Levin, H. Tetsuo Uyeda, P. Otto, R. Hurst, M. B. Robers, K. Zimmerman, L. P. Encell, K. V. Wood, ACS Chem. Biol. 2015, 10, 2316-2324.
H. Deng, Q. Lei, Y. Wu, Y. He, W. Liab, Eur. J. Med. Chem. 2020, 191, 1-16.
H. Park, J. Ha, S. B. Park, Curr. Opin. Chem. Biol. 2019, 50, 66-72.
H. Sun, Y. Shen, G. Luo, Y. Cai, Z. Xiang, BMC Bioinf. 2018, 19, 315.
L. Zhou, Z. Li, J. Yang, G. Tian, F. Liu, H. Wen, L. Peng, M. Chen, J. Xiang, L. Peng, Molecules. 2019, 24, 1714.
Slide decks and webinars on the best practices and case studies are freely accesible on https://www.efmc.info/phenotypic-drug-discovery.
H. Ratni, G. M. Karp, M. Weetall, N. A. Naryshkin, S. V. Paushkin, K. S. Chen, K. D. McCarthy, H. Qi, A. Turpoff, M. G. Woll, X. Zhang, N. Zhang, T. Yang, A. Dakka, P. Vazirani, X. Zhao, E. Pinard, L. Green, P. David-Pierson, D. Tuerck, A. Poirier, W. Muster, S. Kirchner, L. Mueller, I. Gerlach, F. Metzger, J. Med. Chem. 2016, 59, 6086-6100.
S. M. Huang, Y. M. Mishina, S. Liu, A. Cheung, F. Stegmeier, G. A. Michaud, O. Charlat, E. Wiellette, Y. Zhang, S. Wiessner, M. Hild, X. Shi, C. J. Wilson, C. Mickanin, V. Myer, A. Fazal, R. Tomlinson, F. Serluca, W. Shao, H. Cheng, M. Shultz, C. Rau, M. Schirle, J. Schlegl, S. Ghidelli, S. Fawell, C. Lu, D. Curtis, M. W. Kirschner, C. Lengauer, P. M. Finan, J. A. Tallarico, T. Bouwmeester, J. A. Porter, A. Bauer, F. Cong, Nature 2009, 461, 614-620.

Auteurs

Jean Quancard (J)

Global Discovery Chemistry, Novartis Institute For Biomedical Research, Novartis Pharma AG, Novartis Campus, 4056, Basel, Switzerland.

Anders Bach (A)

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark.

Brian Cox (B)

Pharmaceutical Chemistry, School of Life Sciences, University of Sussex, Falmer, East Sussex, BN1 9RH, UK.

Russell Craft (R)

Medicinal Chemistry, Symeres, Kadijk 3, 9747AT, Groningen (The, Netherlands.

Dirk Finsinger (D)

Medicinal Chemistry, Global R&D, Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.

Stéphanie M Guéret (SM)

Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Ingo V Hartung (IV)

Medicinal Chemistry, Global R&D, Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.

Stefan Laufer (S)

Pharmaceutical&Medicinal Chemistry, Institute of Pharmacy & Biochemistry, Tübingen Center for Academic Drug Discovery, Auf der Morgenstelle 8, 72070 Tuebingen, Germany.

Josef Messinger (J)

Medicine Design, Orionpharma, Orionintie 1, 02101, Espoo, Finland.

Gianluca Sbardella (G)

Department of Pharmacy, Epigenetic Med Chem Lab., University of Salerno, Via Giovanni Paolo II 132, 84084, Fisciano-SA, Italy.

Hannes F Koolman (HF)

Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397, Biberach an der Riss, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH